Brief: Ikena Oncology Presents Preclinical Data At The 34Th Eortc-Nci-Aacr Symposium On Novel Tead Inhibitor, Ik-930, Combating Therapeutic Resistance
26/10/2022 12:53
Oct 26 (Reuters) - Ikena Oncology Inc IKNA.O :
* IKENA ONCOLOGY PRESENTS PRECLINICAL DATA AT THE 34TH
EORTC-NCI-AACR SYMPOSIUM ON NOVEL TEAD INHIBITOR, IK-930,
COMBATING THERAPEUTIC RESISTANCE
Source text for Eikon: ID:nGNX223X59
Further company coverage: IKNA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ImageneBio
See all newsU.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma
Brief: ImageneBio Inc - On Oct 23, Elects Not To Renew Agreement With Miragene - SEC Filing
ImageneBio Inc expected to post a loss of $1.56 a share - Earnings Preview
Brief: Ikena Oncology Announces Stockholder Approval Of Merger With Inmagene Biopharmaceuticals